| Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study MJ Armstrong, P Gaunt, GP Aithal, D Barton, D Hull, R Parker, ... The Lancet 387 (10019), 679-690, 2016 | 1874 | 2016 |
| Alcohol, adipose tissue and liver disease: mechanistic links and clinical considerations R Parker, SJ Kim, B Gao Nature reviews Gastroenterology & hepatology 15 (1), 50-59, 2018 | 161 | 2018 |
| Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis R Parker, MJ Armstrong, C Corbett, IA Rowe, DD Houlihan Alimentary pharmacology & therapeutics 37 (9), 845-854, 2013 | 146 | 2013 |
| Mental health disorders and solid-organ transplant recipients C Corbett, MJ Armstrong, R Parker, K Webb, JM Neuberger Transplantation 96 (7), 593-600, 2013 | 116 | 2013 |
| Natural history of histologically proven alcohol-related liver disease: a systematic review R Parker, GP Aithal, U Becker, D Gleeson, S Masson, JI Wyatt, IA Rowe, ... Journal of hepatology 71 (3), 586-593, 2019 | 92 | 2019 |
| Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a … PJ Trivedi, J Tickle, MN Vesterhus, PJ Eddowes, T Bruns, J Vainio, ... Gut 67 (6), 1135-1145, 2018 | 79 | 2018 |
| Alcohol and substance abuse in solid-organ transplant recipients R Parker, MJ Armstrong, C Corbett, EJ Day, JM Neuberger Transplantation 96 (12), 1015-1024, 2013 | 72 | 2013 |
| The role of adipose tissue in fatty liver diseases R Parker Liver Research 2 (1), 35-42, 2018 | 70 | 2018 |
| Targeting inflammation for the treatment of alcoholic liver disease MJ Xu, Z Zhou, R Parker, B Gao Pharmacology & Therapeutics 180, 77-89, 2017 | 70 | 2017 |
| Baseline neutrophil‐to‐lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis EH Forrest, N Storey, R Sinha, SR Atkinson, N Vergis, P Richardson, ... Alimentary pharmacology & therapeutics 50 (4), 442-453, 2019 | 68 | 2019 |
| Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: a worldwide study JP Arab, LA Díaz, N Baeza, F Idalsoaga, E Fuentes-López, J Arnold, ... Journal of hepatology 75 (5), 1026-1033, 2021 | 67 | 2021 |
| Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial MJ Armstrong, D Barton, P Gaunt, D Hull, K Guo, D Stocken, SCL Gough, ... BMJ open 3 (11), e003995, 2013 | 65 | 2013 |
| Provider attitudes and practices for alcohol screening, treatment, and education in patients with liver disease: a survey from the American Association for the Study of Liver … GY Im, JL Mellinger, A Winters, ES Aby, Z Lominadze, J Rice, MR Lucey, ... Clinical Gastroenterology and Hepatology 19 (11), 2407-2416. e8, 2021 | 64 | 2021 |
| Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management MJ Armstrong, JM Hazlehurst, R Parker, E Koushiappi, J Mann, S Khan, ... QJM: An International Journal of Medicine 107 (1), 33-41, 2014 | 61 | 2014 |
| Survival from alcoholic hepatitis has not improved over time E Hughes, LJ Hopkins, R Parker PLoS One 13 (2), e0192393, 2018 | 54 | 2018 |
| Adipocyte death preferentially induces liver injury and inflammation through the activation of chemokine (C‐C motif) receptor 2‐positive macrophages and lipolysis SJ Kim, D Feng, A Guillot, S Dai, F Liu, S Hwang, R Parker, W Seo, Y He, ... Hepatology 69 (5), 1965-1982, 2019 | 53 | 2019 |
| CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease R Parker, CJ Weston, Z Miao, C Corbett, MJ Armstrong, L Ertl, K Ebsworth, ... American Journal of Physiology-Gastrointestinal and Liver Physiology 314 (4 …, 2018 | 53 | 2018 |
| In vitro steroid resistance correlates with outcome in severe alcoholic hepatitis AJ Di Mambro, R Parker, A McCune, F Gordon, CM Dayan, P Collins Hepatology 53 (4), 1316-1322, 2011 | 49 | 2011 |
| Operator training requirements and diagnostic accuracy of Fibroscan in routine clinical practice MJ Armstrong, C Corbett, J Hodson, N Marwah, R Parker, DD Houlihan, ... Postgraduate medical journal 89 (1058), 685-692, 2013 | 44 | 2013 |
| Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British … S McPherson, MJ Armstrong, JF Cobbold, L Corless, QM Anstee, ... The lancet Gastroenterology & hepatology 7 (8), 755-769, 2022 | 43 | 2022 |
Ian A RoweAssociate Professor, University of LeedsVerified email at leeds.ac.uk
